shutterstock_1983054248_jhvephoto
JHVEphoto / Shutterstock.com
12 May 2022Big PharmaMuireann Bolger

Israel targets Teva over MS drug royalties

The state of Israel has sued Teva Pharmaceuticals for $100 million over alleged unpaid royalties relating to its multiple sclerosis drug, Copaxone.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
24 February 2022   Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.
Generics
24 March 2020   Israel has approved generic versions of an HIV antiviral owned by AbbVie for use in treating coronavirus, despite the company still holding patent protection and doubts over its effectiveness.
Biotechnology
18 October 2022   Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.

More on this story

Americas
24 February 2022   Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.
Generics
24 March 2020   Israel has approved generic versions of an HIV antiviral owned by AbbVie for use in treating coronavirus, despite the company still holding patent protection and doubts over its effectiveness.
Biotechnology
18 October 2022   Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.

More on this story

Americas
24 February 2022   Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.
Generics
24 March 2020   Israel has approved generic versions of an HIV antiviral owned by AbbVie for use in treating coronavirus, despite the company still holding patent protection and doubts over its effectiveness.
Biotechnology
18 October 2022   Arbitration panel awarded the sum to Acorda to cover past royalties and interest | Acorda can now source the multiple sclerosis drug elsewhere.